Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

5.6K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

370
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
370
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

5.0K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
5.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

342
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
342
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and molecular improvements in pediatric patients with atopic dermatitis treated with dupilumab: an analysis from the TREATKids registry.

The Journal of investigative dermatology·2026
Same author

[Interdisciplinary Collaboration between Social Service and Case Management in Child and Adolescent Psychiatry: A Qualitative Study of Barriers, Facilitators and the Family Caregiver Perspective].

Psychiatrische Praxis·2026
Same author

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation.

Allergologie select·2026
Same author

Development of a Core Outcome Domain Set for Facial Aging.

JAMA dermatology·2026
Same author

Anthropometric patterns in children with moderate-to-severe atopic dermatitis: Cross-sectional insights from the TREATkids cohort.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Health-related quality of life among patients with colorectal und pancreatic cancer: results from a monocentric registry study.

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))·2026

Related Experiment Video

Updated: Dec 15, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K

Interventions for mycosis fungoides.

Arash Valipour1,2, Manuel Jäger1,3, Peggy Wu4

  • 1Department of Dermatology, Venereology and Allergology, Johann Wolfgang Goethe-University Hospital, Frankfurt am Main, Germany.

The Cochrane Database of Systematic Reviews
|July 8, 2020
PubMed
Summary

This review found a lack of high-quality evidence for treating mycosis fungoides (MF), a type of skin lymphoma. Psoralen plus ultraviolet A (PUVA) remains a recommended first-line treatment due to insufficient evidence challenging its use.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.9K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

Related Experiment Videos

Last Updated: Dec 15, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.9K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

Area of Science:

  • Dermatology
  • Oncology
  • Clinical Trials

Background:

  • Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma, a chronic skin malignancy.
  • Existing therapies offer temporary clinical remission.
  • This is an updated Cochrane Review assessing new interventions for MF.

Purpose of the Study:

  • To evaluate the efficacy and safety of various interventions for all stages of mycosis fungoides.

Main Methods:

  • Systematic review and meta-analysis of 20 randomized controlled trials (RCTs) including 1369 participants.
  • Searched multiple databases up to May 2019 for local or systemic interventions compared to placebo or other treatments.
  • Primary outcomes: quality of life and adverse effects; secondary outcomes: complete response (CR) and objective response rate (ORR).

Main Results:

  • Included RCTs assessed diverse treatments like imiquimod, PUVA, bexarotene, and chemotherapy.
  • Most trials (16/20) had a high risk of bias, limiting reliable comparisons.
  • No significant difference was found between intralesional interferon-alfa (IFN-α) and PUVA; evidence for bexarotene and ECP was very low-certainty.

Conclusions:

  • A significant lack of high-certainty evidence exists for treating MF, hindering treatment decisions.
  • Psoralen plus ultraviolet A (PUVA) remains a recommended first-line treatment as evidence does not challenge its use.
  • Future research should focus on comparing new treatments against PUVA, measuring quality of life and adverse effects.